Villous Adenoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Sources

Aliases & Classifications for Villous Adenoma

MalaCards integrated aliases for Villous Adenoma:

Name: Villous Adenoma ¹¹ ¹⁴

Adenoma, Villous ⁷¹

Adenoma Villous ⁵³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0050869

UMLS ⁷¹ C0206674

Sources

Summaries for Villous Adenoma

Disease Ontology: ¹¹ An adenoma that is located in the colon and other places in the gastrointestinal tract and sometimes in other parts of the body.

MalaCards based summary: Villous Adenoma, also known as adenoma, villous, is related to urethral villous adenoma and urinary bladder villous adenoma. An important gene associated with Villous Adenoma is MUC5AC (Mucin 5AC, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Disease and Homology Directed Repair. The drugs Cianidanol and Epigallocatechin gallate have been mentioned in the context of this disorder. Affiliated tissues include colon, appendix and lymph node, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Reduced mammosphere formation

Sources

Related Diseases for Villous Adenoma

Diseases related to Villous Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 514)

#	Related Disease	Score	Top Affiliating Genes
1	urethral villous adenoma	32.6	KRT7 CEACAM5
2	urinary bladder villous adenoma	32.3	MUC6 MUC5AC KRT7 CEACAM5 CDX2
3	glandular cystitis	30.6	TP53 KRT7 CDX2
4	bile duct cysts	30.4	KRT7 KRAS HRAS CEACAM5
5	rectum neuroendocrine neoplasm	30.3	KRT7 CDX2
6	renal pelvis adenocarcinoma	30.3	KRT7 CEACAM5
7	anal canal adenocarcinoma	30.2	MUC5AC KRT7 CDX2
8	hemorrhoid	30.2	KRT7 CEACAM5 APC
9	intestinal obstruction	30.1	KRT7 CEACAM5 CDX2
10	ureteral benign neoplasm	30.1	TP53 KRT7
11	cholecystitis	30.1	TP53 MUC6 MUC5AC
12	bile duct adenoma	30.1	TP53 MUC6 KRT7
13	small cell carcinoma	30.1	TP53 KRT7 CEACAM5
14	bladder urothelial carcinoma	30.0	TP53 KRAS HRAS CTNNB1
15	transitional cell carcinoma	30.0	TP53 MSH2 MLH1 KRT7
16	appendiceal neoplasm	29.9	KRT7 KRAS HRAS GNAS CEACAM5 CDX2
17	adenosquamous carcinoma	29.9	MUC5AC KRT7 KRAS HRAS CEACAM5
18	papillary adenoma	29.8	TP53 KRT7 KRAS HRAS CEACAM5
19	bladder cancer	29.7	TP53 MSH2 MLH1 KRT7 KRAS HRAS
20	cervical adenocarcinoma	29.7	TP53 MUC5AC KRT7 KRAS CEACAM5 CDX2
21	adenocarcinoma in situ	29.7	TP53 MUC6 KRT7 KRAS HRAS CEACAM5
22	gastrointestinal stromal tumor	29.7	TP53 KRAS HRAS CTNNB1 CEACAM5
23	extrahepatic bile duct adenoma	29.6	PMS2 MSH6 MSH2 MLH1
24	bladder adenocarcinoma	29.6	TP53 KRT7 CTNNB1 CEACAM5 CDX2
25	rectum cancer	29.2	TP53 MUTYH MSH6 MSH2 MLH1 MIR29A
26	ampulla of vater adenocarcinoma	29.1	SMAD4 MUC6 MUC5AC KRT7 KRAS HRAS
27	appendix adenocarcinoma	29.1	TP53 SMAD4 MSH6 KRT7 KRAS HRAS
28	cholangiocarcinoma	29.1	TP53 SMAD4 MUC5AC KRT7 KRAS CTNNB1
29	pseudomyxoma peritonei	28.9	TP53 MUC6 MUC5AC KRT7 KRAS GNAS
30	rectal benign neoplasm	28.8	TP53 PMS2 MSH6 MSH2 MLH1 KRT7
31	desmoid tumor	28.8	TP53 PMS2 MUTYH MSH6 MSH2 CTNNB1
32	adenoma	28.7	TP53 SMAD4 PMS2 MUTYH MUC6 MUC5AC
33	barrett esophagus	28.7	TP53 SMAD4 MUC6 MUC5AC KRT7 CTNNB1
34	adenocarcinoma	28.6	TP53 SMAD4 MUC5AC MSH6 MSH2 MLH1
35	juvenile polyposis syndrome	28.6	SMAD4 PMS2 MUTYH MSH6 MSH2 MLH1
36	appendix cancer	28.5	TP53 SMAD4 MUC6 MUC5AC KRT7 KRAS
37	ampulla of vater cancer	28.5	TP53 SMAD4 MUC6 MUC5AC MLH1 KRT7
38	bile duct cancer	28.4	TP53 SMAD4 MUC6 MUC5AC MIR29A KRT7
39	gastric adenocarcinoma	28.4	TP53 SMAD4 MLH1 KRAS HRAS GNAS
40	colon adenocarcinoma	28.3	TP53 SMAD4 MSH6 MLH1 KRAS HRAS
41	signet ring cell adenocarcinoma	28.0	TP53 PMS2 MUC6 MUC5AC MSH6 MSH2
42	familial adenomatous polyposis	28.0	TP53 SMAD4 PMS2 MUTYH MSH6 MSH2
43	lung cancer susceptibility 3	28.0	TP53 SMAD4 MUC5AC MLH1 KRT7 KRAS
44	diffuse gastric cancer	28.0	TP53 SMAD4 PMS2 MUTYH MSH6 MSH2
45	duodenum adenocarcinoma	27.7	SMAD4 PMS2 MUTYH MUC6 MUC5AC MSH6
46	duodenum cancer	27.7	TP53 SMAD4 PMS2 MUTYH MUC6 MUC5AC
47	mucinous adenocarcinoma	27.5	TP53 SMAD4 PMS2 MUC6 MUC5AC MSH6
48	pancreatic cancer	27.4	TP53 SMAD4 MUC6 MUC5AC MSH6 MSH2
49	rectum adenocarcinoma	27.4	TP53 SMAD4 PMS2 MSH6 MSH2 MLH1
50	colorectal adenocarcinoma	27.4	TP53 SMAD4 PMS2 MSH6 MSH2 MLH1

Graphical network of the top 20 diseases related to Villous Adenoma:

Sources

Symptoms & Phenotypes for Villous Adenoma

GenomeRNAi Phenotypes related to Villous Adenoma according to GeneCards Suite gene sharing:

²⁵ (show all 21)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-1	9.98	MLH1
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-107	9.98	SMAD4
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-11	9.98	SMAD4
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-124	9.98	MLH1
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-133	9.98	APC
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-135	9.98	KRT7
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-192	9.98	APC KRT7
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-195	9.98	MLH1 SMAD4
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-200	9.98	MLH1
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-202	9.98	APC
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-212	9.98	SMAD4
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-25	9.98	SMAD4
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	9.98	SMAD4
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	9.98	CTNNB1
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-68	9.98	KRT7
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-72	9.98	KRT7
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-74	9.98	KRT7
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-78	9.98	MLH1
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-91	9.98	KRT7
20	Reduced mammosphere formation	GR00396-S	9.17	GNAS HRAS KRAS KRT7 MUC5AC MUTYH
21	Synthetic lethal with vaccinia virus (VACV) infection	GR00362-A	8.85	MSH6

MGI Mouse Phenotypes related to Villous Adenoma:

⁴⁵ (show all 13)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.37	APC CDX2 CEACAM5 CTNNB1 GNAS HRAS
2	homeostasis/metabolism	MP:0005376	10.34	APC CDX2 CEACAM5 CTNNB1 GNAS HRAS
3	digestive/alimentary	MP:0005381	10.21	APC CDX2 CEACAM5 CTNNB1 GNAS HRAS
4	cellular	MP:0005384	10.2	APC CDX2 CEACAM5 CTNNB1 GNAS KRAS
5	endocrine/exocrine gland	MP:0005379	10.18	APC CDX2 CEACAM5 CTNNB1 GNAS HRAS
6	normal	MP:0002873	10.16	APC CDX2 CTNNB1 GNAS HRAS KRAS
7	renal/urinary system	MP:0005367	10.1	APC CTNNB1 GNAS HRAS KRAS KRT7
8	muscle	MP:0005369	10.08	APC CEACAM5 CTNNB1 GNAS HRAS KRAS
9	immune system	MP:0005387	10.07	APC CEACAM5 CTNNB1 GNAS KRAS MLH1
10	limbs/digits/tail	MP:0005371	10	APC CDX2 CTNNB1 GNAS KRAS SMAD4
11	hematopoietic system	MP:0005397	9.93	APC CEACAM5 CTNNB1 GNAS KRAS MLH1
12	mortality/aging	MP:0010768	9.83	APC CDX2 CEACAM5 CTNNB1 GNAS HRAS
13	integument	MP:0010771	9.36	APC CTNNB1 GNAS HRAS KRAS MIR29A

Sources

Drugs & Therapeutics for Villous Adenoma

Drugs for Villous Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 6)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Cianidanol

Approved, Withdrawn

Phase 2

154-23-4

9064

2

Epigallocatechin gallate

Investigational

Phase 2

989-51-5

65064

3

Epigallocatechin

Experimental, Investigational

Phase 2

970-74-1

72277

4

Epicatechin

Investigational

Phase 2

490-46-0

58571364 72276

5

Cola

Phase 2

6

Tea

Phase 2

Interventional clinical trials:

#	Name	Status	NCT ID	Phase
1	Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-	Completed	NCT01360320	Phase 2
2	Outcomes of Endoscopic Resection of Mucosal and Submucosal Lesions in the Duodenum and Ampulla	Recruiting	NCT02306603
3	Outcomes of Endoscopic Resection in the Upper Gastrointestinal Tract	Recruiting	NCT02305290
4	Outcomes of Endoscopic Resection of Mucosal and Submucosal Lesions in the Stomach.	Recruiting	NCT02306707

Search NIH Clinical Center for Villous Adenoma

Sources

Genetic Tests for Villous Adenoma

Sources

Anatomical Context for Villous Adenoma

Organs/tissues related to Villous Adenoma:

FMA: Colon

MalaCards : Colon, Appendix, Lymph Node, Pancreas, Small Intestine, Prostate, Adrenal Gland

Sources

Publications for Villous Adenoma

Articles related to Villous Adenoma:

(show top 50) (show all 1016)

#	Title	Authors	PMID	Year
1	Aberrant expression of a human mucin gene (MUC5AC) in rectosigmoid villous adenoma. ⁵³ ⁶²	Buisine MP...Porchet N	8536891	1996
2	Korean guidelines for postpolypectomy colonoscopic surveillance: 2022 revised edition. ⁶²	Kim SY...Korean Association for the Study of Intestinal Diseases	36225130	2022
3	[Relationship of diffusion kurtosis imaging parameters with the pathologic type and prognosis of rectal tumors]. ⁶²	Li J...Cheng JL	36380670	2022
4	Clinicopathological spectrums and prognosis of primary appendiceal adenocarcinoma, goblet cell adenocarcinoma, and low-grade appendiceal mucinous neoplasms. ⁶²	Chen I...Liao X	36454563	2022
5	Mucinous adenocarcinoma of the prostatic urethra after brachytherapy for prostatic adenocarcinoma: a case series. ⁶²	Zhao T...Wu CL	35926810	2022
6	Synchronous primary duodenal papillary adenocarcinoma and gallbladder carcinoma: A case report and review of literature. ⁶²	Chen J...Kong FC	36186218	2022
7	[Korean Guidelines for Postpolypectomy Colonoscopic Surveillance: 2022 Revised Edition]. ⁶²	Kim SY...Korean Association for the Study of Intestinal Diseases	36156035	2022
8	Ten or More Cumulative Lifetime Adenomas Are Associated with Increased Risk for Advanced Neoplasia and Colorectal Cancer. ⁶²	Sullivan BA...Provenzale D	34089135	2022
9	Primary hepatic neuroendocrine carcinoma with colon adenoma: A case report with literature review. ⁶²	Wang Q...Jin Q	35636210	2022
10	Villous adenoma of the prostatic urethra. ⁶²	Ho SY...Lim LY	35381754	2022
11	Prevalence and predictors of colon polyps in patients with skin tags: A cross sectional study. ⁶²	Zaki AM...Elsaie ML	34008290	2022
12	McKittrick-Wheelock syndrome: rectal villous adenoma as a cause of acute renal failure. ⁶²	Ordieres Diaz C...Huergo Fernandez A	35034459	2022
13	Uncommon Association of Mckittrick-Wheelock Syndrome and Clostridioides difficile Infection in Acute Renal Failure. ⁶²	Ciortescu I...Ionescu L	35453832	2022
14	Efficacy and Safety of Exploring Deeper Sections of the Infrapapillary Area of the Duodenum by Using Sedative Esophagogastroduodenoscopy. ⁶²	Hsu MT...Chung WS	35935715	2022
15	CASE STUDY: MAJOR DUODENAL PAPILLA CANCER COMPLICATED BY ACUTE PARACANCROTIC NECROTIZING PANCREATITIS. ⁶²	Dronov OI...Shchyhel IA	35633340	2022
16	McKittrick-Wheelock Syndrome: A Neoplastic Cause of Electrolyte Imbalance. ⁶²	de Sousa Miranda I...Domingos R	35402344	2022
17	Clinical outcomes of endoscopic submucosal dissection for colorectal neoplasms: A single-center experience in Southern Taiwan. ⁶²	Ko CY...Tai WC	36206286	2022
18	Influence of early colorectal cancer component on the positive margins after endoscopic resection: a retrospective study. ⁶²	Zhang QW...Li XB	35093004	2022
19	Urachal mucinous cystadenoma: An exceptional entity. ⁶²	Chaabouni A...Hadjslimene M	34354928	2021
20	Long-term cumulative incidence of metachronous advanced colorectal neoplasia after colonoscopy and a novel risk factor: a cohort study. ⁶²	Omata F...Kumakura Y	34402471	2021
21	Factors predicting occurrence and therapeutic choice in malignant colorectal polyps: a study of 13 years of colonoscopic polypectomy. ⁶²	Cazacu SM...Leru PM	35673811	2021
22	Rare case of advanced rectal cancer with multiple liver and bone metastases presenting with McKittrick-Wheelock syndrome. ⁶²	Fukushima H...Nagahara A	34584983	2021
23	Ileal Tubulo-Villous Adenoma Causing Small Bowel Obstruction in a Virgin Abdomen. ⁶²	Azimi-Ghomi O...Kahane G	34589331	2021
24	Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience. ⁶²	Munari G...Fassan M	33712927	2021
25	Villous adenoma of bladder with uncommon location in a super-aged patient without gross hematuria. ⁶²	Hah YS...Jung HJ	34258525	2021
26	Sarcomatoid urothelial carcinoma arising in the female urethral diverticulum. ⁶²	Park HS	34058799	2021
27	Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications. ⁶²	Cheng L...Zhang S	33674765	2021
28	Microscopic transduodenal excision of an ampullary adenoma: A case report and review of the literature. ⁶²	Zheng X...Yan S	34222457	2021
29	Non-conventional dysplasia in inflammatory bowel disease is more frequently associated with advanced neoplasia and aneuploidy than conventional dysplasia. ⁶²	Lee H...Choi WT	33155325	2021
30	Differential Expression Profiles of Mitogenome Associated MicroRNAs Among Colorectal Adenomatous Polyps. ⁶²	Wallace L...Aikhionbare F	33628862	2021
31	Transanal minimal invasive surgery (TAMIS): safety and feasibility for the resection of benign and malignant lesions of the rectum. ⁶²	Mehraj A...Khan M	34585088	2021
32	Villous adenoma of the renal pelvis: a common entity at an uncommon location. ⁶²	Bharti S...Elhence PA	34307234	2021
33	Giant Villous Adenoma: A Rare Case of Colorectal Adenoma that Mimic Colorectal Cancer. ⁶²	Ferdaus AM...Rahman MH	33397878	2021
34	Villous Adenoma Arising in the Urethra of a Female with Bladder Augmentation History: A Case Report and Review of the Literature. ⁶²	Demir H...Uygun N	32779155	2021
35	Villous adenoma of the urethra. ⁶²	Dowd KE...Bird ET	33678969	2021
36	[Loop colostomy as a risk factor of postoperative ileus in elective colorectal cancer surgery]. ⁶²	Khubezov DA...Kochetkov FD	34941210	2021
37	Giant villous adenoma of the sigmoid colon: an unusual cause of homogeneous, segmental bowel wall thickening. ⁶²	Sacks J...Kirwan A	33299583	2020
38	Reliability in villous tumors staging between preoperative MRI and histopathological examination. ⁶²	Vogrig C...Laurent V	32123949	2020
39	Transanal minimally invasive surgery (TAMIS) for rectal tumor: a case report and literature review. ⁶²	Wang H...Cai Y	33145320	2020
40	Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study. ⁶²	Pires-Luis AS...Hes O	32520749	2020
41	Villous adenoma of the urachus obscuring urachal adenocarcinoma: A case report. ⁶²	Nishikawa Y...Isoyama T	32477881	2020
42	Adult duodenal intussusception with horizontal adenoma: A rare case report. ⁶²	Wang KP...Jin C	32874987	2020
43	Colonoscopy in patients with psoriasis before the initiation of treatment with biological agents. ⁶²	Tamer F...Yuksel ME	32506694	2020
44	A rare case of huge villous adenoma of the renal pelvis deforming the abdominal wall. ⁶²	Stoykov B...Mateva S	32309146	2020
45	Nomograms that predict the survival of patients with adenocarcinoma in villous adenoma of the colorectum: a SEER-based study. ⁶²	Tang CT...Chen Y	32600342	2020
46	Lessons of the month 2: McKittrick-Wheelock syndrome: Case report of a patient declining resection of a large villous adenoma. ⁶²	Murugachandran J...Gannon D	32414717	2020
47	Endoscopic resection of a prolapsing giant villous adenoma of the supraanal rectum. ⁶²	Zimmer V...Eltze E	31447294	2020
48	Evaluation of a Deep Neural Network for Automated Classification of Colorectal Polyps on Histopathologic Slides. ⁶²	Wei JW...Hassanpour S	32324237	2020
49	Villous Morphology in Urinary Bladder Biopsy: An Approach to Diagnosis. ⁶²	Mitra S...Kaur G	31409167	2020
50	A histopathological rarity: Primary signet ring cell carcinoma arising within a colonic villous adenoma. ⁶²	Jacob S...Zayyani NR	32031145	2020

Sources

Genes for Villous Adenoma

Genes related to Villous Adenoma (0 elite genes):

(show all 21)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MUC5AC	Mucin 5AC, Oligomeric Mucus/Gel-Forming	Protein Coding	12.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10767823 8536891
2	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	9.64	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8012980
3	MIR29A	MicroRNA 29a	RNA Gene	6.96	DISEASES inferred ¹⁴ ¹⁴
4	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	6.53	DISEASES inferred ¹⁴
5	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.4	DISEASES inferred ¹⁴
6	CDX2	Caudal Type Homeobox 2	Protein Coding	6.27	DISEASES inferred ¹⁴
7	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	6.22	DISEASES inferred ¹⁴
8	GNAS	GNAS Complex Locus	Protein Coding	6.16	DISEASES inferred ¹⁴
9	MLH1	MutL Homolog 1	Protein Coding	6.16	DISEASES inferred ¹⁴
10	MIR532	MicroRNA 532	RNA Gene	6.12	DISEASES inferred ¹⁴ ¹⁴
11	MUC6	Mucin 6, Oligomeric Mucus/Gel-Forming	Protein Coding	5.93	DISEASES inferred ¹⁴
12	KRT7	Keratin 7	Protein Coding	5.87	DISEASES inferred ¹⁴
13	TP53	Tumor Protein P53	Protein Coding	5.84	DISEASES inferred ¹⁴
14	MSH2	MutS Homolog 2	Protein Coding	5.48	DISEASES inferred ¹⁴
15	MSH6	MutS Homolog 6	Protein Coding	5.46	DISEASES inferred ¹⁴
16	MUTYH	MutY DNA Glycosylase	Protein Coding	5.45	DISEASES inferred ¹⁴
17	CTNNB1	Catenin Beta 1	Protein Coding	5.42	DISEASES inferred ¹⁴
18	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	5.38	DISEASES inferred ¹⁴
19	SEPTIN9	Septin 9	Protein Coding	5.36	DISEASES inferred ¹⁴
20	SMAD4	SMAD Family Member 4	Protein Coding	5.33	DISEASES inferred ¹⁴
21	APBA1	Amyloid Beta Precursor Protein Binding Family A Member 1	Protein Coding	5.29	DISEASES inferred ¹⁴

Sources

Variations for Villous Adenoma

Sources

Expression for Villous Adenoma

Search GEO for disease gene expression data for Villous Adenoma.

Sources

Pathways for Villous Adenoma

Pathways related to Villous Adenoma according to GeneCards Suite gene sharing:

(show all 40)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.6	TP53 SMAD4 PMS2 MUTYH MUC6 MUC5AC
2	Homology Directed Repair ⁶⁶ Show member pathways Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex ⁶⁶ DNA Double-Strand Break Repair ⁶⁶ DNA Repair ⁶⁶ G2/M DNA damage checkpoint ⁶⁶ HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) ⁶⁶ HDR through MMEJ (alt-NHEJ) ⁶⁶ Processing of DNA double-strand break ends ⁶⁶	13.15	TP53 PMS2 MUTYH MSH6 MSH2 MLH1
3	TCR Signaling (Qiagen) ⁶⁴ Show member pathways Fc-EpsilonRI Pathway ⁶⁴ ITK and TCR Signaling ⁶⁴ PDGF Pathway ⁶⁴ PKC-Theta Pathway ⁶⁴	12.85	TP53 MSH6 MSH2 MLH1 KRAS HRAS
4	Alzheimer's disease and miRNA effects ⁷⁴ Show member pathways Alzheimer's disease ⁷⁴	12.77	MIR29A KRAS HRAS CTNNB1 APC
5	fMLP Pathway ⁶⁴ Show member pathways CXCR4 Pathway ⁶⁴ Huntington's Disease Pathway ⁶⁴ Internalin Pathway ⁶⁴ Signal transduction Activation of PKC via G-Protein coupled receptor ²²	12.69	TP53 KRAS HRAS GNAS CTNNB1
6	Homologous DNA Pairing and Strand Exchange ⁶⁶ Show member pathways Defective Base Excision Repair Associated with NEIL1 ⁶⁶ Defective homologous recombination repair (HRR) due to BRCA2 loss of function ⁶⁶ Diseases of Base Excision Repair ⁶⁶ Diseases of DNA Double-Strand Break Repair ⁶⁶ Diseases of DNA repair ⁶⁶ Fanconi anemia pathway ⁶¹ Fanconi Anemia Pathway ⁶⁶ HDR through Homologous Recombination (HRR) ⁶⁶ HDR through Single Strand Annealing (SSA) ⁶⁶ Impaired BRCA2 binding to RAD51 ⁶⁶ Presynaptic phase of homologous DNA pairing and strand exchange ⁶⁶	12.68	PMS2 MUTYH MSH6 MSH2 MLH1
7	DNA repair pathways, full network ⁷⁴ Show member pathways Defective Mismatch Repair Associated With MSH2 ⁶⁶ Defective Mismatch Repair Associated With MSH3 ⁶⁶ Defective Mismatch Repair Associated With MSH6 ⁶⁶ Diseases of Mismatch Repair (MMR) ⁶⁶ Dual Incision in GG-NER ⁶⁶ Homologous recombination ⁷⁴ Mismatch Repair ⁶⁶ Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) ⁶⁶ Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) ⁶⁶ Non-homologous end joining ⁷⁴ Nucleotide excision repair ⁷⁴ Nucleotide excision repair in xeroderma pigmentosum ⁷⁴ Nucleotide Excision Repair Pathway ⁶⁴	12.56	MLH1 MSH2 MSH6 MUTYH PMS2
8	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.5	TP53 MSH2 KRAS HRAS CTNNB1
9	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.43	TP53 KRAS HRAS CTNNB1
10	Human Embryonic Stem Cell Pluripotency ⁶⁴ Show member pathways Factors Promoting Cardiogenesis in Vertebrates ⁶⁴	12.42	SMAD4 GNAS CTNNB1 APC
11	DNA Damage ³	12.41	TP53 MUTYH MSH6 MSH2 MLH1
12	WNT Signaling ⁶⁴	12.38	TP53 GNAS CTNNB1 APC
13	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.38	TP53 KRAS HRAS CTNNB1
14	CLEC7A (Dectin-1) signaling ⁶⁶ Show member pathways Alternative NF-kappaB pathway ⁶¹ CLEC7A/inflammasome pathway ⁶⁶ C-type lectin receptors (CLRs) ⁶⁶	12.37	MUC6 MUC5AC KRAS HRAS
15	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.37	TP53 SMAD4 KRAS HRAS CTNNB1 APC
16	Base excision repair ⁷⁴ Show member pathways Abasic sugar-phosphate removal via the single-nucleotide replacement pathway ⁶⁶ APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway ⁶⁶ Cell cycle Transition and termination of DNA replication ²² Displacement of DNA glycosylase by APEX1 ⁶⁶ DNA mismatch repair ⁷⁴ Gap-filling DNA repair synthesis and ligation in GG-NER ⁶⁶ Mismatch Repair in Eukaryotes ⁶⁴ PCNA-Dependent Long Patch Base Excision Repair ⁶⁶ POLB-Dependent Long Patch Base Excision Repair ⁶⁶ Resolution of Abasic Sites (AP sites) ⁶⁶ Resolution of AP sites via the multiple-nucleotide patch replacement pathway ⁶⁶ Resolution of AP sites via the single-nucleotide replacement pathway ⁶⁶	12.31	PMS2 MUTYH MSH6 MSH2 MLH1
17	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.23	TP53 SMAD4 MSH6 MSH2 MLH1 KRAS
18	Wnt / Hedgehog / Notch ³	12.18	SMAD4 CTNNB1 CDX2 APC
19	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.1	CTNNB1 HRAS KRAS SMAD4 TP53
20	Integrated breast cancer pathway ⁷⁴	12.02	CTNNB1 KRAS MSH2 MSH6 SMAD4 TP53
21	Direct p53 effectors ⁶¹	11.98	TP53 PMS2 MSH2 MLH1 APC
22	G12-G13 in Cellular Signaling ⁶⁴	11.91	KRAS HRAS CTNNB1 APC
23	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.76	MSH2 MSH6 TP53
24	Thyroid hormones production and peripheral downstream signaling effects ⁷⁴	11.76	CTNNB1 HRAS TP53
25	DNA IR-damage and cellular response via ATR ⁷⁴	11.74	TP53 MSH2 MLH1
26	DNA damage response (only ATM dependent) ⁷⁴	11.74	TP53 SMAD4 KRAS HRAS CTNNB1 APC
27	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.72	TP53 KRAS HRAS
28	Head and neck squamous cell carcinoma ⁷⁴	11.67	TP53 SMAD4 KRAS HRAS CTNNB1
29	Endoderm differentiation ⁷⁴	11.66	APC CTNNB1 SMAD4
30	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ⁶¹	11.66	APC CTNNB1 HRAS
31	Serotonin HTR1 group and FOS pathway ⁷⁴ Show member pathways Serotonin receptor 2 and ELK-SRF/GATA4 signaling ⁷⁴ Serotonin receptor 4/6/7 and NR3C signaling ⁷⁴	11.58	KRAS HRAS GNAS
32	Colorectal Cancer Metastasis ⁶⁴	11.49	TP53 SMAD4 MSH6 MSH2 MLH1 KRAS
33	Doxorubicin Pathway, Pharmacokinetics ⁶⁰ Show member pathways Doxorubicin Pathway (Cancer Cell), Pharmacodynamics ⁶⁰	11.36	TP53 MSH2 MLH1
34	Bladder cancer ⁷⁴	11.35	TP53 KRAS HRAS
35	Integrated cancer pathway ⁷⁴	11.31	MSH2 MSH6 TP53
36	Envelope proteins and their potential roles in EDMD physiopathology ⁷⁴	11.28	SMAD4 KRAS HRAS
37	Platinum Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.2	PMS2 MSH6 MSH2 MLH1
38	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	11	APC CTNNB1 HRAS KRAS SMAD4
39	TNF-alpha signaling pathway ⁷⁴ Show member pathways RAS GTPase cycle mutants ⁶⁶ Signaling by RAS GAP mutants ⁶⁶ Signaling by RAS GTPase mutants ⁶⁶	10.75	KRAS HRAS
40	Defective Mismatch Repair Associated With PMS2 ⁶⁶ Show member pathways Defective Mismatch Repair Associated With MLH1 ⁶⁶	10.2	PMS2 MLH1

Sources

GO Terms for Villous Adenoma

Cellular components related to Villous Adenoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	MutLalpha complex	GO:0032389	9.46	PMS2 MLH1
2	MutSalpha complex	GO:0032301	9.26	MSH6 MSH2
3	mismatch repair complex	GO:0032300	9.02	PMS2 MSH2 MLH1

Biological processes related to Villous Adenoma according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell population proliferation	GO:0008285	10.2	TP53 SMAD4 MIR29A HRAS CTNNB1 APC
2	intrinsic apoptotic signaling pathway	GO:0097193	9.91	TP53 MSH6 HRAS
3	cellular response to DNA damage stimulus	GO:0006974	9.91	TP53 PMS2 MUTYH MSH6 MSH2 MLH1
4	determination of adult lifespan	GO:0008340	9.88	TP53 MSH6 MSH2
5	isotype switching	GO:0045190	9.85	MLH1 MSH2 MSH6
6	positive regulation of helicase activity	GO:0051096	9.83	MSH6 MSH2
7	positive regulation of isotype switching to IgA isotypes	GO:0048298	9.8	MSH2 MLH1
8	hair follicle placode formation	GO:0060789	9.69	GNAS CTNNB1
9	maintenance of DNA repeat elements	GO:0043570	9.65	MSH6 MSH2
10	somatic hypermutation of immunoglobulin genes	GO:0016446	9.56	PMS2 MSH6 MSH2 MLH1
11	somatic recombination of immunoglobulin gene segments	GO:0016447	9.55	MSH6 MSH2 MLH1
12	somatic recombination of immunoglobulin genes involved in immune response	GO:0002204	9.5	MSH2 MLH1
13	mismatch repair	GO:0006298	9.32	PMS2 MUTYH MSH6 MSH2 MLH1

Molecular functions related to Villous Adenoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	chromatin binding	GO:0003682	10.23	TP53 SMAD4 MSH6 MSH2 MLH1 CTNNB1
2	MutSalpha complex binding	GO:0032407	9.85	PMS2 MUTYH MLH1
3	oxidized purine DNA binding	GO:0032357	9.8	MSH2 MSH6 MUTYH
4	ATP-dependent DNA damage sensor activity	GO:0140664	9.76	PMS2 MSH6 MSH2 MLH1
5	single guanine insertion binding	GO:0032142	9.73	MSH6 MSH2
6	single thymine insertion binding	GO:0032143	9.71	MSH6 MSH2
7	MutLalpha complex binding	GO:0032405	9.65	MSH2 MSH6 MUTYH
8	guanine/thymine mispair binding	GO:0032137	9.43	MSH6 MSH2 MLH1
9	mismatched DNA binding	GO:0030983	9.1	PMS2 MSH6 MSH2 MLH1

Sources

Sources for Villous Adenoma

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

MCID: VLL006 MIFTS: 42	Villous Adenoma Categories: Cancer diseases, Gastrointestinal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables